GNW-Adhoc: New Novotech report shows 1,000 clinical HIV studies worldwide

^BOSTON, Dec. November 30, 2023 (GLOBE NEWSWIRE) — Novotech, (https://novotech-

cro.com/reports/gall-bladder-cancer-global-clinical-trial-

landscape?utm_source=PRESS+RELEASE&utm_medium=PR&utm_campaign=GBC+DISEASE+REPORT

&utm_term=DOWNLOAD-REPORT&utm_content=GBC) the leading Asian-

Pacific-focused biotech CRO with global

Implementing Capacities, today released the latest report on the global

2023 clinical trial landscape published on HIV, a disease

which now affects more than 39 million people.

Novotech’s team of research analysts provides these expert reports on a monthly basis

available completely free of charge. These reports provide up-to-date insights into the

global activity of clinical trials and show in which regions the

highest study volumes have been recorded and what factors are behind them

Trends stand. They address the hurdles that biotech companies face

are confronted with certain therapeutic areas and discuss future ones

Therapy paths and investment trends.

According to the HIV Global Clinical Trial Landscape Report, the biopharmaceutical industry

Since 2018, over 1,000 clinical HIV studies have been initiated worldwide. The distribution

of the studies is as follows: Asia Pacific accounts for 29% of the

Studies, followed by Europe with 28% and North America with 26%, while the rest

in the world (ROW) accounts for a moderate share of 17%.

In Asia Pacific, mainland China had the highest at 45%

Study share. Within Europe, Spain, France, recorded this

United Kingdom, Italy and Germany have the most HIV studies. Under

Among the ROW countries, South Africa leads the way with 31% of HIV studies.

The report also reviewed caseload and mortality data for 2022

Regions.

* South Africa had 7.6 million cases and 45,000 AIDS-related deaths,

which highlights the serious impact within the country.

* India reported 2.5 million cases and 40,000 deaths, a

reflects a significant HIV burden.

* There were 1.2 million HIV cases in the United States, resulting in 19,986

led to deaths.

* Thailand reported 560,000 cases and 11,000 deaths.

* In Western Europe, France has had 200,000 cases and 880 deaths.

* Spain reported 150,000 cases and 640 deaths.

* Italy has had 140,000 cases and 550 deaths.

* Malaysia reported 86,000 cases and 2,500 deaths.

* New Zealand had comparatively 3,600 cases and 100 deaths

lower numbers.

The report analyzed global study risk and found that in the region

Asia Pacific with their large population and comparatively smaller ones

Study quantity the risk of competing studies is lower. The density of studies

in this region is more than six times lower than in the USA and about three times

lower than in Europe.

A review of HIV investment data between 2019 and 2022 found:?China

experienced a significant influx of venture capital with investments amounting to

totaling $1,534.8 million, while the United States spent $540.5 million

dollars to fight HIV. These investments mean

a global commitment to revolutionizing HIV prevention and treatment

and awareness-raising strategies.”

The report also examined developments in treatment and found

that advances in?HIV treatment come from innovative

Drug formulations through to therapeutic vaccines and genetic

Editing technologies range, reflecting ongoing efforts, uncovered

Meeting needs and making people living with HIV more accessible and effective

to provide options. The treatment paradigm changes with it

injectable options such as Cabenuva and Lenacapavir and offers alternatives for

the daily pill routine.”

“A weekly dose of islatravir and the experimental CRISPR

based gene editing method show the potential to alleviate HIV

treatment burden and provide long-lasting cures,” the report said.

An examination of the therapeutic pipeline as part of the report found

that it?across the spectrum of HIV drug development by phase one

promising progression with 50 drugs in preclinical phases

There are 61 in phase I studies and 15 in combined phase I/II studies.

Additionally, 34 drugs are in Phase II, 13 are in Phase III, with 9

approved and 61 drugs already on the market, which is one

“reflects a robust HIV treatment landscape.”

Download the report here (https://novotech-cro.com/reports/hiv-

global clinical trial

landscape?utm_source=PR+HIV&utm_medium=PR+HIV&utm_campaign=PR+HIV)

Novotech employs more than 3,000 people in 25 countries

34 branches, including in the USA, Greater China, South Korea,

Australia, New Zealand and Europe.

The CRO offers biotechnology companies a unique and unparalleled experience

Offering early to late phase contract research services

the USA and Europe, with a focus on the Asia-Pacific region

is where the company has a good reputation in terms of implementation

high-quality accelerated clinical trials.

Novotech has been recognized with numerous awards for its industry-leading contributions

Awards honored including the 2023 CRO Leadership Award and

the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence Award for

2022 and 2023. The company has also been awarded the Asian Award every year since 2006.

Pacific Contract Research Organization Company of the Year Award.

The company’s commitment to collaboration is evident in the

50 Leading Site Partnership agreements signed in the last three years

has signed.

Contact person for media

David James

[email protected] (mailto:[email protected])

AU: +61 2 8218 2144

USA: +1 415 951 3228

Asia: +65 3159 3427

About Novotech Novotech-CRO.com (https://novotech-cro.com/reports/gall-bladder-

cancer-global-clinical-trial-

landscape?utm_source=PRESS+RELEASE&utm_medium=PR&utm_campaign=GBC+DISEASE+REPORT

&utm_term=DOWNLOAD REPORT&utm_content=GBC)

Founded in 1997, Novotech is a global clinical

Full-service contract research organization (CRO) focused on

Collaboration with biotech companies focused on development

of advanced and novel therapeutics at every stage.

Recognized for its industry-leading contributions, Novotech has numerous

Received prestigious awards including the CRO Leadership Award

2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023 and

since 2006 the Asia-Pacific Contract Research Organization Company of the Year

Award.

The company offers a full range of services including

Laboratories, Phase I facilities, drug development consulting and

regulatory expertise, and has experience with over 5,000 clinical

Projects, including phase I to IV clinical trials and

Bioequivalence studies. With a presence in 34 locations and a dedicated

With a team of more than 3,000 professionals worldwide, Novotech is a trusted one

strategic end-to-end partner of choice.

For more information or to speak to an expert team member,

visit www.Novotech-CRO.com (http://www.novotech-cro.com/)

A photo accompanying this announcement is available

at https://www.globenewswire.com/NewsRoom/AttachmentNg/440766ee-b4d9-4f23-

a450-5efeb980cc1e

°

ttn-28